In spring 2026, in Baicheng, Jilin province, China, a 2,200-mu industrial complex hums day and night. Inside its five newly built fermentation lines, sweet corn-glucose liquid teems with Corynebacterium glutamicum bacteria, converting sugar into lysine — an additive indispensable to twenty-first-century pig and poultry farms. This is the daily reality of Meihua Biological's Baicheng base annual 600,000-tonne lysine project. When fully ramped in early 2026, plus the existing 700,000-tonne Jilin capacity, Meihua's lysine production in Jilin alone reaches 1.3 million tonnes — nearly 30% of global lysine capacity.

In the same time window, in a Brussels meeting room of the European Commission's DG Trade, representatives of Europe's last remaining lysine producer (formerly Ajinomoto Eurolysine, now renamed Eurolysine) are submitting a new round of complaints about Chinese amino acid import prices. Anti-dumping duties between 47.7% and 58.3% took effect on July 12, 2025, for five years. Now the Europeans request an anti-absorption investigation — alleging Chinese producers cut export prices to neutralize the duty wall. In April 2026, the Commission accepted the request and reopened the case.

These two events — one inside a Chinese factory, the other inside a European meeting room — tell the same story: China's amino acid industry in 2026, marked by domestic expansion, overseas price pressure, policy backlash, and an industry transitioning from "selling factories" to "selling strains."

China's amino acid global standing has quietly switched ranks over the past fifteen years. Before 2010, global lysine was a four-way fight among the US, Japan, Korea, and Europe. By 2023, China alone held 76% of global lysine capacity and 93% of threonine. By 2024, China's feed amino acid supply reached 4.89 million tonnes, up 12.9% year on year, raising global share to 70%.

This report does not aim to answer "how big is China's amino acid industry" — that question is settled. It addresses several real questions: With major-product (lysine, threonine) capacity now in surplus and prices floored, where does the industry go? Will small varieties (valine, tryptophan, arginine, alanine, isoleucine) and pharmaceutical-grade become the new growth engine? Will synthetic biology era strain breeding and conversion-rate gains sustain the next cycle? Where do the EU anti-dumping and anti-absorption cases land? And what are the true moats of Meihua, Yipin (Xinghu), Fufeng, and Angel?

From a corn kernel in a field to a pre-mix bag in a feed mill, amino acid is the deeply hidden industrial ruler. It welds food security, biomanufacturing, animal nutrition, pharmaceutical-grade synthesis, export trade, and geopolitics — seemingly unrelated topics — into one industrial chain.

Chapter 1 Industry Overview: Key 2025 Numbers in the Global and Chinese Amino Acid Map

In 2025, China's amino acid industry shows complex curves in capacity, demand, exports, prices, and profits. To make sense of it, one must place it in the global context.

Global structure

By scientific definition, amino acids are protein's building blocks. Hundreds occur in nature; about twenty are industrially produced. They split into four families by use:

  1. Feed-grade amino acids — lysine, threonine, valine, tryptophan, methionine, arginine, isoleucine. Over 80% of global amino acid output. They are the "chemical equivalent" of feed protein sources (soybean meal, fishmeal, rapeseed meal). Pure amino acid supplementation improves protein replacement efficiency and reduces nitrogen emission. This is the largest downstream of Chinese feed amino acids in the past three decades.

  2. Food-grade amino acids — primarily monosodium glutamate (MSG), flavor nucleotides (IMP/GMP), yeast extract (YE). These are the food industry's hidden flavor enhancers and nutrition fortifiers.

  3. Pharmaceutical-grade amino acids — compound amino acid infusion, parenteral nutrition, post-surgery recovery, medical aesthetics ingredients. Highest unit price, fastest growth, highest technical barrier.

  4. Chemical and material-grade amino acids — alanine for nylon 56, biodegradable plastics; isoleucine, tryptophan as precursors of cosmetic active peptides. The synthetic biology era's emerging direction.

Key 2025 numbers in China

  • 2024 China total amino acid demand: 5.6152 million tonnes;
  • Market size: RMB 60.862 billion;
  • Glutamate (including MSG) 33.35%, lysine 32.79%, threonine 10.11% — together ~76%.

Global share:

  • 2023 lysine: 76% China; threonine: 93% China;
  • Valine and tryptophan also above 50%.

Capacity:

  • End-2024 China lysine total capacity: ~3.5 million tonnes, +17% YoY;
  • Threonine capacity: ~1.08 million tonnes;
  • Valine capacity: 302,000 tonnes; production 191,000 tonnes;
  • Tryptophan global share: 41.4% (2023).

Exports:

  • Jan-Nov 2024: lysine HCl and esters total exports 1.0085 million tonnes (+16.07% YoY); export value USD 1.276 billion (+26.59%);
  • Jan-Oct 2024: threonine exports 592,300 tonnes (+29% YoY).

Together these show China amino acid has moved from "self-sufficient" through "import substitution" into "global supplier" — export share consistently exceeds 30%, with some small varieties above 50%.

Major global players

  • China camp: Meihua Biological, Xinghu Technology (including Yipin Biological), Fufeng Group, Huaheng Biological, CJ Shenyang (Korean), Shouguang Jinyumi, Lianhua Health.
  • Overseas camp: CJ CheilJedang (Korea — global lysine 3rd, tryptophan 1st, valine 1st, nucleotide 1st); Ajinomoto (Japan — 20% global lysine + 35% threonine); Daesang (Korea); ADM (US, has exited lysine HCl 98%); Evonik (Germany, methionine 1st).

2025 price action

Two halves: first half remained at floor levels (lysine 98% at RMB 7,800-8,500/t, threonine 98.5% at RMB 11,000-12,000/t), near cash-cost. Second half saw rebound — EU AD duty effective July, overseas capacity contraction (CJ Daesang Ajinomoto retreating), corn price recovering (Q1 RMB 2,123→2,263/t). Lysine rebounded to RMB 9,500-10,500; threonine to RMB 13,500-14,500.

That price recovery drove headline P&L. Meihua FY2025 revenue RMB 24.209 billion (-3.43%), but net profit RMB 3.281 billion (+19.72%) — from second-half volume-and-price recovery. Fufeng FY2025 revenue ~RMB 27.9 billion (+0.4%), with animal nutrition (lysine, threonine, tryptophan) up 20.5% to RMB 10.527 billion — the year's biggest highlight.

But this is just the first half of a longer story. The 2026 variables are: Baicheng 600,000-tonne ramp-up, Xinghu Heilongjiang 450,000-tonne new project, EU anti-absorption outcome, Huaheng valine and alanine expansion, pharmaceutical-grade amino acid sprint.

Chapter 2 Upstream: From a Corn Kernel to a Sugar Tank

The fermentation-based amino acid chain starts in a cornfield, ends in a one-gram white powder in a pre-mix bag. The longest, most critical, most underrated segment is "corn → glucose syrup." It sets the industry's cost floor and explains why all major plants sit in the corn belt — Meihua in Tongliao and Baicheng, Fufeng in Wulanchabu and Wujiaqu, Yipin/Xinghu in Chifeng, Ningxia, Heilongjiang, Huaheng in Qinhuangdao.

Corn intensity per tonne

Per tonne lysine HCl 98.5%: ~2.5 tonnes corn starch sugar (glucose), or about 3.5-4 tonnes of raw corn. Per tonne threonine: ~3 tonnes corn. Per tonne valine: 5-7 tonnes (lower conversion). Per tonne tryptophan: 6-8 tonnes (smallest variety, lowest conversion).

When corn price moves by RMB 100/t, lysine cost moves by RMB 350-400/t. This is why 2024's corn price drop from RMB 2,500 to 2,090/t squeezed industry margin — cost fell RMB 300+ but selling price fell RMB 600-700, pushing the industry to cash-cost line.

Corn to glucose process

Standard flow: corn cleaning → soaking → crushing → separation (germ, bran, fiber) → starch milk → liquefaction → saccharification → glucose syrup → fermenter.

  • Soaking: 0.1-0.2% SO2 sulfites to soften corn, release starch;
  • Liquefaction: α-amylase, breaks starch to short-chain dextrins, 105℃ for 90 seconds, pH 6;
  • Saccharification: glucoamylase (β-amylase + pullulanase combo), hydrolyzes dextrins to glucose, 60℃ for 36-48 hours, pH 4.5;
  • Endpoint glucose DE 95-98 (DE = Dextrose Equivalent) — the feed for downstream fermentation.

Stable DE within ±1 takes decades of process accumulation. Hundreds of corn starch sugar makers exist, but only dozens can stably feed amino acid fermenters — small-mid players have wide DE swings, high impurity counts, high ash content; entering a fermenter is disaster.

Strain breeding and conversion

Strain is the industry's highest moat. Lysine producer strain: Corynebacterium glutamicum, first industrialized by Japan's Kyowa, later evolved by ADM, Ajinomoto, CJ. China's heads (Meihua, Yipin) have walked their own metabolic paths. Current industrial strains in top Chinese plants reach 250 g/L acid production, sugar-to-acid conversion 65-68%, near 75% theoretical limit.

Threonine strain: E. coli with metabolic engineering, 200+ g/L production, ~65% conversion.

Valine strain: 100-130 g/L, conversion 30-40% — far lower than lysine, the reason for higher unit cost.

Tryptophan strain: 50-65 g/L, conversion 18-22% — lowest among major varieties, why tryptophan price is RMB 70,000-100,000/t versus lysine's RMB 8,000-10,000/t.

Water-electricity-steam consumption

Per tonne lysine:

  • Water: 30-40 t;
  • Electricity: 1,500-2,000 kWh;
  • Steam: 8-12 t;
  • Pure oxygen: 600-800 Nm3 (from on-site air separation);
  • Liquid ammonia: 200-300 kg (for pH adjustment).

These items account for 15-20% of total cost. Hence the geographic logic — Inner Mongolia, Ningxia, Xinjiang, Northeast — areas with cheap coal-fired or renewable power plus corn and water resources.

Byproduct utilization

Per tonne lysine produces ~0.8-1.2 t mycelial protein cake (low-end feed protein, RMB 1,500-2,000/t). Plus ammonium sulfate (RMB 800-1,200/t for fertilizer), corn gluten meal, corn oil, corn fiber, biogas. Top plants run dedicated byproduct lines. "Main product margin is thin; byproducts decide net" — an industry saying with real weight.

Chapter 3 Process Moats: Fermenters, Purification, and Strain Secrecy

If strain is the highest moat, then fermenter design + purification + strain secrecy are the mid-tier moats — together forming the real barrier that keeps outsiders out.

Fermenter design: from 200 m3 to 800 m3

Pre-2000 China amino acid fermenters were 100-200 m3. Each batch lasted 36-48 hours, producing 5-8 tonnes lysine. Core designs came from Germany's GEA, Switzerland's Bühler, US Pall Corporation.

From 2005, China developed indigenous 300-500 m3 tanks. The hard part is not "how big" — any tank-builder can scale — but "in-tank mass transfer + sterile operation." Bigger tanks mean more dead zones, uneven oxygenation, larger temperature gradients, and bigger losses from contamination.

Post-2020 saw 800 m3 lysine fermenters at Meihua Tongliao and Yipin Ningxia: single-tank output 30-50 tonnes; electricity down ~20%; steam down 15%. But contamination risk doubled — one event loses 30-50 t product and a week of cleaning.

The real test is "can you run an 800 m3 tank continuously for a year with under 2% contamination rate." Only three or four Chinese plants pass.

Purification: from broth to 98.5% crystal

Broth from the fermenter contains 10-15% target amino acid + 5-10% residual sugar + 5% protein + lots of water and salts. To refine to 98.5% lysine HCl crystal:

  1. Filtration/centrifugation — separate biomass from broth (10kDa ultrafiltration mainstream);
  2. Ion exchange — adsorb amino acid (charged) on resin, elute (strong-acid cation resin like DOWEX 50WX8);
  3. Concentration — multi-effect evaporator to 30-40% solution;
  4. Crystallization — cooling or concentration-cooling combined;
  5. Centrifugation — separate crystal from mother liquor;
  6. Drying — air or fluidized bed to <0.5% moisture;
  7. Sieving and packing — 25 kg bags or 1 t super-sacks.

Each step loses 1-3%, full process yield 88-92%. The 92% vs 88% gap translates to tens of millions of yuan per year for a major plant.

Strain secrecy regime

Strain is the industry's most secretive asset. R&D cycle 5-10 years, investment tens of millions to over a hundred million yuan. One leak — ex-employee taking it, outsider replicating it, industrial espionage — zeros the investment. Hence draconian secrecy:

  • Inoculation room: physical isolation, fewer than five people, full video surveillance, no personal electronics;
  • Strain library: lab-grade liquid nitrogen storage, backups across multiple geographic locations;
  • Production: daily inoculation by dedicated staff, strain never leaves the inoculation room;
  • Employee contracts: core R&D non-compete 5-10 years, among the longest in Chinese manufacturing;
  • Retired strains: kept as historical and legal evidence, periodically deposited with notary public.

Real cases exist — strain disputes, similarity rulings of 99%, settlements in the tens of millions of yuan. Strain secrecy in this industry is governance, not just technology.

Unit consumption comparison

Item Top Chinese Tier-2 Chinese Overseas
Corn/t 3.5 t 3.8 t 3.6-4.0 t
Water/t 30 t 35-40 t 35-45 t
Electricity/t 1,500 kWh 1,800 kWh 1,800-2,200 kWh
Steam/t 8 t 10-12 t 10-14 t
Sugar-to-acid conv. 67% 60% 60-65%
Full yield 91% 87% 88-90%
Cost (with overhead) RMB 6,800/t RMB 7,800/t RMB 8,500-9,500/t

Top Chinese tonne cost is RMB 1,000 below tier-2 Chinese, RMB 2,000-3,000 below overseas. ADM exited lysine HCl 98% in 2021 because its cost was 30-40% above Chinese tops — unprofitable without subsidy.

Chapter 4 Major Players: Meihua, Yipin, Fufeng, Huaheng, and Global Benchmarks

The Chinese amino acid head consists of six: Meihua Biological, Xinghu Technology (with Yipin Biological), Fufeng Group, Huaheng Biological, CJ Shenyang (Korean), Lianhua Health. Plus four global benchmarks: CJ CheilJedang, Ajinomoto, Daesang, Evonik. Ten companies form the global map.

4.1 Meihua Biological (600873)

Meihua is the absolute king of Chinese amino acid. FY2025:

  • Revenue RMB 24.209 bn (-3.43%);
  • Net profit attributable to parent RMB 3.281 bn (+19.72%);
  • Non-recurring net profit RMB 2.205 bn (-18.22%).

Segment:

  • Feed amino acid (lysine, threonine, tryptophan, etc.): RMB 10.714 bn (-6.21%), 44.2% of revenue;
  • Flavor enhancers (MSG, IMP/GMP): RMB 7.005 bn (-3.44%);
  • Pharmaceutical-grade amino acid: RMB 740 mn (+55.45% — fastest growing segment);
  • Xanthan gum and other gums.

Capacity end-2025:

  • Lysine (Jilin Tongliao + Baicheng): Baicheng 600k tonnes trial Q4 2025, ramped Q1 2026; combined Jilin 1.3 mn tonnes, ~30% of global;
  • Threonine (Tongliao): ~300k tonnes;
  • MSG (Tongliao + Xinjiang Wujiaqu): Tongliao 500k tonnes upgrade online 2024, total 750k tonnes, global single-product max;
  • Xanthan gum: global leader;
  • Pharmaceutical-grade amino acid: high growth.

Strategy: from "selling product" to "selling tech + selling product + going global" — licensing strains to small varieties partners, expanding in Southeast Asia and Central Asia to bypass anti-dumping.

4.2 Xinghu Technology (600866, with Yipin Biological)

In 2022, Guangdong Xinghu Tech acquired 99.22% of Yipin Biological via share issue + cash, expanding total assets 5x and revenue 10x. Yipin had long been China's #2 amino acid player:

  • Lysine capacity 820,000 t (#2 globally, ~20% share);
  • Threonine 265,000 t (#2);
  • Valine 20,000 t;
  • MSG and nucleotide too — together with Meihua and Fufeng, the "MSG big three."

June 2025: Xinghu announced up to RMB 3.3 bn investment in 450k t amino acid project in Heilongjiang (Mudanjiang) — 200k t feed-grade threonine + 250k t MSG, operated by Heilongjiang Yipin Biological. Largest single threonine new project in China 2025-2027.

Yipin/Xinghu strategy: broadest geographic footprint + earliest going-global moves. Bases in Inner Mongolia Bayannur, Ningxia Yinchuan, Liaoning Jinzhou, Guangxi Fangchenggang, Fujian Zhangzhou — widest distribution among Chinese players.

4.3 Fufeng Group (0546.HK)

Fufeng is the earliest Chinese amino acid IPO overseas (HKEX 2007). FY2025:

  • Total revenue ~RMB 27.9 bn (+0.4%);
  • Food additives (mainly MSG) RMB 13.389 bn (-6.8%); MSG revenue RMB 10.25 bn, sales volume 1.8041 mn t (+10.1%), average price RMB 5,681/t (-15.4%);
  • Animal nutrition (lysine, threonine, tryptophan): up 20.5% to RMB 10.527 bn;
  • Xanthan gum average price RMB 18,037/t (-16.1%);
  • Net profit attributable to parent +6.6%.

Fufeng is China amino acid's first cross-border capacity transferer — Kazakhstan Almaty base 2026 commissioning, targeting Russia, Europe, Turkey markets. Strategic significance is not only geography but also bypassing the EU anti-dumping duty (duty is on "China-origin" lysine, not Kazakhstan-origin).

Xanthan gum patent settlement in 2025: Meihua paid Fufeng RMB 233 mn — the industry's largest patent case ended in settlement.

4.4 Huaheng Biological (688639)

China synthetic biology leader; STAR Market IPO 2021. Distinct from "scale-cost" players, Huaheng walks "synthetic biology + high-margin small varieties":

  • Alanine series (L-Ala, DL-Ala, β-Ala): global #1, biggest profit source;
  • L-valine: feed-grade 20,000 t;
  • L-isoleucine: feed + food-grade;
  • L-tryptophan: feed-grade;
  • L-arginine: food + pharmaceutical;
  • Industrial serine: chemical raw material.

Core competence: strain platform. Team from CAS Microbiology Institute and Tsinghua Life Sciences. On alanine, Huaheng pioneered "anaerobic fermentation alanine" — energy use 70% lower than aerobic, conversion from 40% to 95%+. In 2025 expanding alanine from 50k t toward 120k t, and L-valine from 20k t toward 50k t. Logic: when major products are surplus and floored, the next growth is small varieties + high unit price + synthetic biology.

4.5 Lianhua Health (600186)

Old "Lianhua MSG" parent. Crashed in 2000s; rebuilt via debt restructuring. Now ~250,000 t MSG, part of "MSG big three" with Meihua and Fufeng. No major feed amino acid presence.

4.6 CJ Shenyang Biological

Korean CJ CheilJedang's wholly-owned China sub. Shenyang is CJ's global valine main line — nominal capacity 50,000 t/y, largest single-firm valine capacity in China.

4.7 Global benchmarks

CJ CheilJedang (Korea): another true king. Global #1 in lysine, tryptophan, valine, nucleotide. 2025 BIO segment hurt by Chinese low prices. Strengths: high-margin amino acids + global brand customers (Cargill, ADM, JBS, Tyson).

Ajinomoto (Japan): 20% global lysine + 35% threonine. FY2024 Q3 cumulative revenue JPY 1.164 trillion (+1% YoY); business profit JPY 145.9 bn (+5%). Strategy: from feed-grade gradually retreating to food + pharmaceutical + cosmetic-grade — classic Japanese upgrade path.

Daesang (Korea): December 2025 acquired Germany's AMINO GmbH for KRW 50.2 bn — pivoting to pharmaceutical-grade. 2025 Q3 materials segment KRW 202.4 bn (-15% YoY) on Chinese low-price impact.

Evonik (Germany): global #1 methionine. May 2025 raised MetAMINO (DL-methionine 99% feed-grade) price 5-8% globally. Antwerp plant shut 6-7 weeks Sep-Oct for upgrade. Product carbon footprint 35% below industry average.

ADM (US): stopped lysine HCl 98% production in 2021. Pivoted to high-end animal nutrition, pet food, plant protein, oils — a typical sample of Western majors being pushed out by Chinese low cost.

Chapter 5 Downstream I: Feed Additives — Swine, Broilers, Aquaculture, Ruminants

Cut globally by downstream: feed accounts for 80% of amino acid use. China 2024 feed amino acid supply 4.89 mn t, market RMB 50 bn — largest, most stable, most growth-certain downstream.

5.1 Science of feed amino acids

Twenty amino acids form protein. Pigs need ten essential ones; chickens eleven; fish ten or so. Feed formulation matches "amino acid demand pattern" of growth stage. Traditional: soybean meal + corn + fishmeal. Problem: excess non-essentials + deficient essentials — excess gets excreted as urea nitrogen (pollution), deficient limits growth.

Industrial amino acid lets formulators replace soybean meal with corn + low soybean meal + pure amino acid (Lys + Thr + Met + Trp + Val). Low-protein amino acid balanced diet: total protein from 18% to 13-15%; soybean meal -15-30%; nitrogen emission -20-30%; growth performance unchanged or better.

Policy driver: Ministry of Agriculture and Rural Affairs' 2021 Plan to Reduce Corn and Soybean Meal in Feed — pushing low-protein diets and non-grain protein (microbial protein, insect protein, single-cell protein) as food security pillars.

5.2 Swine feed

Largest segment. China ~420 mn pig stock, ~700 mn annual slaughter. Per fattening pig (130 kg): 280 kg feed; pure Lys 1.8 kg, Thr 0.9 kg, Val 0.6 kg, Trp 0.15 kg, Met 0.7 kg.

700 mn pigs × per-head needs: Lys 1.26 mn t; Thr 0.63 mn t; Val 0.42 mn t; Trp 105k t; Met 490k t.

5.3 Broiler feed

Fastest-growing. ~6 bn white-feather broilers + 2 bn yellow-feather broilers. Per 2.5 kg white broiler: 4 kg feed; Lys 36 g, Thr 24 g, Val 16 g, Trp 4 g, Met 16 g.

6 bn broilers × per-head: Lys 216k t; Thr 144k t; Val 96k t; Trp 24k t; Met 96k t.

Laying hens — 1.2 bn stock, 32 mn t eggs annual production — also stable. Layer dietary Lys at 0.75% lower than broiler but cumulative use is still major.

5.4 Aquaculture feed

China aquaculture annual output ~68 mn t, world #1. Aqua feed amino acid structure differs:

  • Fish: highest Met + Lys (replacing fishmeal saves cost);
  • Crustaceans: high Arg (different ammonia metabolism);
  • Shellfish: balanced but small absolute volumes.

2024 China aqua feed ~24 mn t: freshwater fish 12 mn t; marine fish 2.5 mn t; shrimp 3.5 mn t; crab 0.8 mn t; others 5.2 mn t.

5.5 Ruminant feed

Ruminants (cattle, sheep) differ — rumen microbes synthesize most essentials. But studies show dairy and beef cattle have significant demand for "rumen-protected amino acids" (RPAA) — coated to bypass rumen and absorb in small intestine. Methionine RPAA at RMB 80k-120k/t (vs regular Met RMB 20k-25k/t). Evonik, Adisseo (China Bluestar), Kemin, Balchem dominate. China import share still high, big substitution opportunity.

5.6 Feed company landscape

Top Chinese feed firms by amino acid procurement:

  • New Hope Liuhe: ~30 mn t feed/yr, amino acid ~350-400k t/yr;
  • Haid Group: ~27 mn t, ~300k t amino acid;
  • Wens Foodstuff: ~22 mn t self-mixed, ~250k t amino acid;
  • CP Group (China): ~15 mn t;
  • Da Bei Nong, Tongwei, Tang Renshen: 5-10 mn t each.

Procurement: framework agreements, quarterly settlement, futures hedging. Volatile amino acid prices transmit fast through pre-mix and full-feed pricing to farming downstream.

Chapter 6 Downstream II: Food-grade (MSG/YE/Bakery) + Pharmaceutical-grade (Amino Acid Infusion)

Feed is biggest but food + pharmaceutical have higher unit price, margin, growth. This chapter covers both.

6.1 Food-grade: MSG's stable market

MSG (monosodium glutamate, chemical name sodium glutamate) is the longest-history industrial amino acid product. In 1908, Prof. Kikunae Ikeda of Tokyo Imperial University isolated MSG from kombu broth, discovering "umami" as the fifth basic taste. In 1909, Ajinomoto commercialized it. Today global MSG consumption 4 mn t, China ~2.5 mn t (60%).

China MSG market:

  • Total stable, structure shifting: household end declining 20 years (replaced by chicken essence, compound seasonings); food industry and food service growing — total stable at ~2.5 mn t/yr;
  • Highly concentrated: Fufeng (capacity 2 mn t), Meihua (750k t — Tongliao single-line global max), Lianhua Health (250k t) = >90% of China share;
  • Volatile prices: 2025 Fufeng MSG average RMB 5,681/t (-15.4% YoY); volume 1.8 mn t (+10.1%) — classic "price war for share."

IMP/GMP — flavor nucleotides — are MSG's siblings. Umami strength tens to hundreds of times MSG; synergy multiplies. Used in chicken essence, compound seasoning, instant noodle packs. Meihua global #1 in IMP/GMP at ~70k t.

6.2 Yeast extract YE: another flavor enhancer

Past decade's fastest-growing flavor enhancer. By yeast autolysis or enzymolysis, releases internal amino acids + peptides + nucleotides. Versus MSG: multi-component natural umami, "clean label" friendly, lower sodium, more natural perception.

China YE absolute king: Angel Yeast (600298). 2025:

  • H1 revenue RMB 7.9 bn (+10.1% YoY), net profit RMB 799 mn (+15.7%);
  • 9M revenue RMB 11.787 bn (+8.01%), net profit RMB 1.116 bn (+17.13%);
  • Yeast protein exports to 40+ countries (protein powder, baking, sports drinks, plant-based foods);
  • Brand value RMB 20.268 bn, China food category #1 for years.

Angel product matrix: fresh yeast + active dry yeast (baking); YE (food flavor); yeast extract (pharma excipients); yeast protein (supplements); yeast β-glucan (immunity); nutritional yeast (B vitamins). Moat: yeast strain + 40 years global fermentation experience + broadest product matrix. Different from bulk amino acid players — higher margin, more diversified customers, stronger brand.

6.3 Pharmaceutical-grade: high price, high barrier, high growth

Global pharma-grade amino acid market 2023 RMB 48.175 bn, forecast 2029 RMB 61.747 bn. China share ~15% but growth outpaces global.

Core application: compound amino acid infusion — parenteral nutrition for surgery, trauma, ICU, infection, cancer. China annual production >120 mn bottles, largest parenteral nutrition product.

Products by composition:

  • Compound 18AA-VII: 18-amino-acid standard, clinical universal;
  • Compound 14AA: minus some BCAA, for specific conditions;
  • Compound 6AA: for liver disease, adjusted BCAA + aromatic ratio;
  • Single amino acid infusion (Arg, Gln, etc.): specialty clinical use.

18AA-VII China market structure: Hisco 58.88% (clear leader); Green Cross 28.43%; Fubon Pharma 12.69%.

Raw material side: globally Ajinomoto, Kyowa Hakko Kirin, Evonik. Chinese suppliers: Meihua pharmaceutical-grade segment 2025 +55.45% to RMB 740 mn — fastest segment, key strategic transformation.

Other high-growth sub-segments:

  • BCAA sports nutrition (Leu+Ile+Val);
  • L-glutamine immunomodulator;
  • L-arginine men's health;
  • L-theanine relaxation;
  • L-tryptophan sleep aid.

2024 China supplement amino acid market ~RMB 8 bn, +15% YoY — active substitution and brand-building zone.

6.4 Medical aesthetic grade: collagen + amino acid

Past five years: recombinant collagen feedstock (glycine + proline + hydroxyproline peptide synthesis). Jinbo Bio, Giant Biogene, Bloomage Bio. Market small (~5,000 t/yr amino acid use) but high unit price (RMB 200k-500k/t medical aesthetic-grade, 20-50x bulk) — highest-margin segment.

6.5 Functional foods + condiments

Last sub: peptide condiments (chicken broth essence, bone broth, seafood essence), acidulants (citric, fumaric — same process family), thickeners. Smaller than MSG but transitional product for big amino acid plants going to end-consumer.

Common logic across food + pharma: from "selling pure amino acid" to "selling formulation + brand + clinical data." Biggest industrial upgrade direction.

Chapter 7 The Platform Perspective: Mining 4.8 Million Factories for Amino Acid Downstream

Chapter 7 changes view — from "industry view" to "scenario view." How does a real sales or procurement manager precisely find his downstream or upstream customers in China's complex factory map?

Why does this matter specifically for amino acid? Because downstream is extremely fragmented:

  • Tens of thousands of feed mills nationwide, but only thousands are truly industrial pre-mix mills;
  • Food factories using MSG, YE, compound seasoning span thousands of niche scenarios;
  • Pharma-grade downstream concentration is high (top three = 90%), but supplements outside hospitals are extremely fragmented;
  • Chemical/material-grade downstream is "synthetic biology new material" firms — small volume, high unit price, costliest to mine.

Tianxia Gongchang is the 4.8-million in-production factory B2B platform — its key difference from Qichacha, Tianyancha, Aiqicha is: those are all-business databases (companies, shops, individual proprietors, traders all mixed in); this platform only includes real in-production manufacturing factories. That filtering distinction matters fundamentally for ToB industrial sales mining.

Four real amino acid sales/procurement scenarios:

7.1 Scenario 1: an amino acid plant's salesperson finds nationwide feed mill customers

A lysine sales rep targets 200 new feed mill customers/month. Traditional: industry association name lists + tradeshows + Yellow Pages + asking distributors. Year-end: under 100 effective customers, 5% conversion.

Using the platform:

  • Step 1: search "compound feed," "pre-mix," "pig feed," "chicken feed," "aqua feed" keywords — return thousands of real factories nationwide;
  • Step 2: filter by geography (province, city, county) + scale (registered capital, headcount) — lock this month's target provinces;
  • Step 3: platform directly provides factory address, phone, contact, products, upstream-downstream relations — sales reps can pre-book, route-plan, batch-visit.

"Scenario mining + geography filtering + scale tiering" lifts visit efficiency from "100 effective" to "400 effective" — 4x. Core driver: data precision.

7.2 Scenario 2: food factory procurement finds compound seasoning/YE suppliers

A hotpot base food factory needs YE, IMP/GMP, compound seasoning. Traditional: tradeshows, industry seniors, random quotes. With the platform: search "yeast extract," "seasoning," "MSG," "flavor nucleotide" — returns nationwide compliant in-production factories with detail. Compare quotes from five to ten suppliers in one go; minimize single-source risk.

7.3 Scenario 3: pharma-grade amino acid maker finds downstream pharma/supplement factories

A pharma-grade amino acid producer sells to drug factories and supplement factories. Traditional: GMP drug factory lists, OTC distributors. With the platform: search "pharmaceutical amino acid," "compound amino acid," "parenteral nutrition," "protein supplement" — returns nationwide GMP-certified pharmaceutical factories, supplement factories, nutrition supplement factories. Add GMP and export certification filters — get final target customer list directly.

7.4 Scenario 4: synthetic biology new material maker finds nylon 56/biodegradable plastic downstream

An alanine producer sells to nylon 56 makers or biodegradable plastic makers. Traditional: new material associations, NEV plastics suppliers. With the platform: search "nylon," "biodegradable plastic," "engineering plastic" — returns nationwide composite materials factories filterable by capacity, application, revenue. Sales directly book and connect based on real factory data.

7.5 Platform usage core logic

Abstract the four scenarios: core value to amino acid industry is:

  • Filter precision: only real in-production factories, filter out trader/shop noise;
  • Data depth: each factory's products, capacity, upstream-downstream, customer relationship are structured fields;
  • Search convenience: keyword + region + scale + qualification multi-dimensional filtering, second-level returns;
  • Scenario fit: matches typical ToB industrial sales, procurement, market research, industry research scenarios.

For amino acid where "upstream highly concentrated, downstream extremely fragmented," this matters especially. Top firms (Meihua, Fufeng, Yipin) lock head feed mills via framework agreements + futures hedging. But mid-small feed mills, food factories, supplement makers, new material makers — that long-tail is the real incremental ground each top firm competes for. Effective long-tail mining determines whether top firms keep growing 2026-2030.

Chapter 8 Substitution Nodes: From "Catching Up" to "Defining Global Prices"

China amino acid's "import substitution" story splits in two. First phase: "upward substitution" — from zero, grabbing share from foreign giants. This finished for lysine and threonine — by 2023, China global share 76% and 93%. Second phase: "global definition" — through capacity dominance, plus strain, tech, and pharma upgrade to capture pricing power and brand premium. Just starting.

8.1 Major product substitution: basically complete

Timeline:

  • 1980s: MSG/glutamate industrialized in China, but lysine/threonine still imported;
  • 1995-2000: Shouguang Jinyumi, Fufeng, Changchun Dacheng start small lysine production;
  • 2000-2010: Meihua, Yipin, CJ Shenyang reach 30-50 mn-t-class capacity;
  • 2010-2020: China lysine global share rises from 30% to 60%;
  • 2020-2023: another step up to 76%;
  • 2024-2025: enters "global supplier" phase, exports stable at 30-40% of capacity.

Threonine story more extreme — 2023 93% in China; overseas basically abandoned. One of China's highest-share global industrial products (alongside rare earths, PV, EV batteries).

The milestone is not capacity numbers but pricing power — post-2020, global lysine price is set by Chinese head firm price sheets. Overseas (CJ, Ajinomoto, Daesang) can only follow. Hence overseas 2025 contractions — they're price takers, not setters, and the floor squeezes their margin.

8.2 Small variety substitution: in progress

  • Valine: 2024 China capacity 302k t, >70% global. CJ Shenyang (Korean in China) #1, Meihua/Huaheng/Yipin following. Tech mature, price linked to lysine.
  • Tryptophan: 2023 global share 41.4% (fastest-growing small variety). Meihua, Yipin, Huaheng, CJ Shenyang top four China.
  • Arginine: pharma + food split. Huaheng, Ningxia Yipin major; overseas Kyowa and Ajinomoto.
  • Alanine: Huaheng global #1; from 50k t to 120k t expanding. Downstream beyond feed: nylon 56 monomer, biodegradable plastic, cosmetic peptide.
  • Isoleucine + leucine: BCAA trio sports nutrition; China substitution from 20% to 60%+. International brands (Ajinomoto, Kyowa) still dominate pharma-grade + high-purity sports nutrition.

Small variety features: small per-product scale (thousands to tens of thousands tonnes); high unit price (RMB 70k-200k/t); high margin (>30%). Past 5 years' main profit increment for heads — bulk amino acid floored, small varieties' high margin supports overall profit.

8.3 Pharmaceutical-grade substitution: just started

Low substitution. Raw material side dominated by Ajinomoto, Kyowa, Evonik, Sigma-Aldrich. Meihua pharma amino acid 2025 RMB 740 mn, +55.45% YoY — small base, fastest growth.

Difficulty isn't capacity but "pharma-grade standards" — heavy metals, microbial count, endotoxin, pyrogens all stricter than feed. cGMP certification, traceable raw materials, batch-to-batch QC. Can't be a simple chemical plant upgrade — must rebuild from workshop, equipment, training, QC system to pharma standard. But once done, payoff huge — pharma-grade prices 5-10x feed-grade, margin 3-5x. Meihua 2025 growth validates: pharma-grade is the most important growth pole for next 5 years.

8.4 Rumen-protected amino acid substitution: still blank

Substitution rate <20%. Evonik, Adisseo (China Bluestar), Balchem, Kemin remain dominant. Chinese domestic R&D in universities and startups; no large-scale industrial production yet. Clear blank for next 5 years.

8.5 Strain itself's substitution: from passive to active

Most hidden: strain substitution. Past 30 years, Chinese plant starter strains came from Kyowa, ADM, Ajinomoto. Today Chinese top firm strains walk their own metabolic paths; some firms start reverse licensing — Huaheng licenses alanine strains overseas; Meihua licenses small-variety strains to SE Asian factories. The marker of "China amino acid" moving from capacity output to technology output.

Together: China amino acid "substitution" has moved from "replacing imports" to "defining global". But "defining global" isn't only capacity — it means full grab of pricing power, tech power, brand power, standard-setting power. Biggest strategic shift of next 5 years.

Chapter 9 Capacity Expansion: Meihua Tongliao, Yipin Chifeng, Xinghu Zhaoqing, Overseas Bases

2026-2028 global amino acid map will be reshaped by several new projects.

9.1 Meihua Tongliao — extreme version of mega-base

Tongliao, the "holy land" of Chinese amino acid. Eastern Inner Mongolia, adjacent to Jilin Baicheng and Heilongjiang — corn belt + wind power + industrial land + policy support made it China's biggest amino acid base.

End-2025 Meihua Tongliao "Head Economy Industry Park" — global largest single amino acid base:

  • MSG: 750k t/y (single-line global max);
  • Lysine: 700k t/y (Meihua Jilin main);
  • Threonine: 300k t/y;
  • Xanthan: 80k t/y;
  • IMP/GMP: 70k t/y;
  • Microbial protein: hundreds of thousands of tonnes/y.

September 2024: Tongliao + Baicheng "Meihua Head Economy Industry Park" Phase 1 broke ground — 600k t/y lysine + supporting starch sugar, air separation, power, water treatment. Q4 2025 trial, Q1 2026 ramp. Post-ramp Meihua Jilin total lysine 1.3 mn t — ~30% global.

Tongliao base core competitiveness: logistics (corn from adjacent belt, <50 km); energy (wind + coal-fired, 15% below other bases); industrial integration (starch + fermentation + extraction + byproducts all in one park); scale (50 mn t single line, 12% lower cost than 10 mn t single line); policy support (Inner Mongolia + Tongliao tax breaks).

9.2 Yipin Chifeng + Ningxia — multi-base portfolio advantage

Yipin (Xinghu sub) base spread:

  • Inner Mongolia Bayannur: MSG + lysine main, late 90s startup;
  • Ningxia Yinchuan: threonine + valine main, ~300k t threonine;
  • Liaoning Jinzhou: lysine (Japan-Korea export);
  • Guangxi Fangchenggang: MSG export base, SE Asia focused;
  • Fujian Zhangzhou: IMP/GMP + food-grade;
  • Heilongjiang Mudanjiang: under construction 2025-2027, threonine + MSG;
  • Chifeng base (cooperative with Bailong Foods): MSG + lysine.

Yipin core strategy: geographic dispersion + logistics dominance — bases in all corn belt areas, avoiding single-base regional volatility. Multi-base ensures export port flexibility (Fangchenggang, Zhangzhou, Qingdao, Lianyungang all accessible).

June 2025 announcement: "Xinghu plans up to RMB 3.3 bn investment in 450k t amino acid project in Heilongjiang" — Mudanjiang, RMB 3.3 bn investment, 200k t feed-grade threonine + 250k t MSG, operated by Heilongjiang Yipin; expected 2027 commissioning.

If on schedule, Yipin + Xinghu threonine in early 2027 reaches 465k t (265k existing + 200k new) — global #2 after Meihua Tongliao.

9.3 Xinghu Zhaoqing base — food-grade and high-value-added

Xinghu Tech headquarters base in Guangdong Zhaoqing — main battlefield for food-grade and high-value-added. Products: food-grade lysine/threonine; IMP/GMP; citric/fumaric/malic acid (same fermentation process); arginine (small scale).

Zhaoqing is Xinghu's "R&D center + high-value-added product base" — smaller than Yipin's Inner Mongolia/Ningxia but higher unit price. Strategic shift over next 5 years: gradually transitioning from "Yipin bulk amino acid" to "Zhaoqing high-value-added food + pharma."

9.4 Overseas bases: Fufeng Kazakhstan + Meihua potential

2026 real suspense: overseas bases. Fufeng Kazakhstan Almaty base 2026 commissioning, MSG + lysine, targeting Russia, Europe, Middle East. Core value: bypass EU anti-dumping (duty on "China-origin," Kazakhstan-origin not included).

Kazakhstan strengths:

  • Corn: Kazakhstan is Central Asia's biggest corn/grain producer;
  • Energy: natural gas + electricity below China;
  • Logistics: shorter Caspian-Russia-Turkey-Europe routes;
  • Political stability: lower geopolitical risk than Russia;
  • Investment environment: "Belt and Road" Central Asia cooperation framework.

Meihua hasn't publicly confirmed overseas plans, but industry expects Meihua to build in SE Asia (Vietnam, Indonesia) or Central Asia (Kazakhstan, Uzbekistan) 2027-2029. Same logic — bypass duties + capture SE Asia and Middle East markets.

9.5 Capacity expansion global impact

Putting the four expansion points together:

  • Meihua Tongliao+Baicheng ramp → China lysine from 3.5 to 4.1 mn t (+17%);
  • Xinghu Yipin Heilongjiang → threonine from 1.08 to 1.28 mn t (+19%);
  • Fufeng Kazakhstan → overseas +300-500k t MSG + lysine;
  • Huaheng alanine → global alanine from 80k to 150k t (+88%);
  • Pharma-grade → China total expected to double 2026-2028.

Means 2026-2028 global supply continues to expand; price pressure may return to floor. But not necessarily bad — depends on demand response: China hog stock recovery (2026 7.2 bn slaughters target); global aqua growth (~4-5%/yr); low-protein diet further adoption (replacing soybean meal, raising amino acid unit use); overseas market (South America, SE Asia, India) expansion; pharma/cosmetic/food-grade increment.

If demand keeps up, 2026-2028 industry can sustain 5-7% annual growth; if not, prices return to 2024-2025 floor, margin pressed near cash cost.

Chapter 10 Price Cycle: Full Replay of Lysine/Threonine 2024-2026

Telling the past three years' Chinese amino acid price story is the best way to understand 2026 dynamics.

10.1 2024: the "darkest hour"

Worst price year of past decade. Three causes:

  • Corn price fell all year: from RMB 2,500 to 2,090/t (-16.4%);
  • Pre-overseas-anti-dumping last rush: Chinese makers accelerated exports, pushing global inventory to historical highs;
  • Domestic feed demand weak: hog stock at historical lows from ASF + price cycle.

Lysine full-year average:

  • Q1: RMB 8,500-9,200/t;
  • Q2: RMB 7,800-8,500/t;
  • Q3: RMB 7,500-8,200/t (near cash cost);
  • Q4: RMB 7,300-8,000/t (some tier-2 makers losing money).

Threonine:

  • Q1: RMB 12,500-13,500/t;
  • Q2: RMB 11,500-12,500/t;
  • Q3: RMB 10,800-11,800/t;
  • Q4: RMB 11,000-12,000/t.

2024 was "cash cost line test":

  • Meihua, Fufeng, Yipin (top three): tonne cost ~RMB 6,800-7,000, marginally profitable;
  • Tier-2 (Shouguang Jinyumi, CJ Shenyang, parts of Huaheng): tonne cost RMB 7,500-8,000, some lines lossy;
  • Overseas (CJ, Daesang, Ajinomoto): tonne cost RMB 8,500-9,500, mostly lossy or break-even.

ADM's 2021 exit from lysine HCl 98% was fully absorbed by 2024 — overseas had to reduce utilization to limit losses.

10.2 2025: bottom rebound

First-half cash-cost line continued; second-half rapid rebound.

Half-year cash-cost line

Q1 2025: corn small rebound 2,123→2,263 (+6.6%); amino acid prices sluggish: Lys 7,800-8,500, Thr 11,000-12,000. Industry margin thin.

Q2 2025: Fufeng and Meihua maintain high utilization, but tier-2 cut production; overseas ADM further reduced lysine capacity; prices near cash cost.

Three-way rebound

Q3 2025: three-way amplifier:

  1. EU AD effective July 12: 47.7-58.3%, 5 years. China-to-EU lysine prices raised;
  2. Overseas capacity adjustment: CJ, Daesang, Ajinomoto collective contraction, global supply -15-20k t;
  3. China feed demand recovery: hog stock recovering Q3; aqua feed steady growth.

Lysine Q4 to RMB 9,500-10,500; threonine to RMB 13,500-14,500.

2025 financial impact

Price rebound directly in headline P&L:

  • Meihua: net profit RMB 3.281 bn (+19.72%), non-recurring 2.205 bn (-18.22%, reflecting first-half pressure);
  • Fufeng: animal nutrition +20.5% to RMB 10.527 bn — year's biggest highlight;
  • Xinghu: profit improvement via Yipin business support.

10.3 2026: the "balance period"

First-half "high"

  • EU AD + anti-absorption keeps overseas export prices high;
  • Hog slaughter continues recovery, feed demand steady;
  • Corn price RMB 2,300-2,500/t (climate + inventory dependent);
  • Lysine RMB 10,000-11,500/t;
  • Threonine RMB 14,000-15,500/t;
  • Top firms first-half net +20-30% YoY.

Second-half "new capacity shock"

  • Meihua Baicheng 600k t ramps in Q3-Q4;
  • Xinghu Heilongjiang 450k t possibly partial commissioning;
  • Global supply re-expansion, price pressure returns;
  • Lysine back to RMB 9,000-10,500;
  • Threonine back to RMB 13,000-14,500.

Full-year 2026: "high first-half, second-half retreat, overall annual average slightly up YoY."

10.4 Lagged cost transmission

Amino acid prices vs corn aren't synchronized but lagged:

  • Corn up → 1-2 months later amino acid up;
  • Corn down → 2-3 months later amino acid down (slower);
  • Up-transmission ~80%; down ~60% (makers prefer holding price).

This "lagged + asymmetric" mechanism lets head firms capture "time-spread profit."

10.5 Cycle core rules

Abstract: amino acid cycle is not "agricultural cycle" (intra-year) but "industrial cycle" (2-3 year expansion + 1-2 year absorption). Floor by cash cost; ceiling by demand elasticity + substitute (soybean meal) + overseas supply. Real industry profit source: byproduct full utilization + unit consumption optimization + small variety margin — not bulk price swings.

Understanding this cycle explains why Meihua, Fufeng, Xinghu stayed profitable through 2024 — low tonne cost, full byproduct use, larger small-variety mix.

Chapter 11 Policy: Low-Protein Diet Standard, EU AD, Export Rebate, Carbon Neutrality

Four major policy events shape 2026-2030 China amino acid trajectory.

11.1 Low-protein diet standard: state strategy to reduce soybean meal dependence

"Low-protein diet" official push started 2021 — Ministry of Agriculture and Rural Affairs' Plan to Reduce Corn and Soybean Meal in Feed. Core goals: reduce soybean meal import dependence (China >80% soybean import dependency, biggest food security gap); promote low-protein diet (16-18% protein down to 13-15%); promote non-grain protein substitution (microbial, insect, single-cell, algae); raise feed formulation science.

Real impact:

  • Central fiscal support for low-protein diet R&D and demonstration projects continuously rising;
  • Annual "Feed Protein Saving Demonstration Project" lists released, top feed firms lead;
  • Industry standardization bodies push Low-Protein Amino Acid Balanced Diet Formulation Guidelines and other group standards;
  • Universities (China Agricultural University, Sichuan Agricultural University, Huazhong Agricultural University, Northeast Agricultural University) low-protein research projects multiply.

2023-2025 results:

  • National feed average protein from 17.2% (2020) to 15.3% (2025);
  • Soybean meal use from 70 mn t (2020) to 58 mn t (2025);
  • But pure amino acid additive use from 2.9 mn t (2020) to 4.89 mn t (2025), +69%.

Direct "demand-side push" — the deeper low-protein adoption, the higher amino acid unit use. Foundation of 2020-2025's 10%+ annual domestic demand growth.

11.2 EU anti-dumping and anti-absorption

Biggest trade shock to China amino acid exports in five years. Timeline:

  • April 2024: Metex Noovistago (later Eurolysine) files complaint;
  • May 2024: Commission opens investigation;
  • Early 2025: provisional duty;
  • June 2025: Member States approve final duty, Regulation EU 2025/1330;
  • July 12, 2025: duty effective, 47.7-58.3%, 5 years;
  • February 11, 2026: Eurolysine files anti-absorption request;
  • April 2026: Commission accepts, reopens.

Anti-absorption is more aggressive — if exporters "absorb" the duty via price cuts, more duty may be added. If final ruling against Chinese makers, duty could go from 47.7-58.3% to 70-80%.

Chinese response strategies:

  1. Overseas bases (Fufeng Kazakhstan, Meihua potential SE Asia);
  2. Price negotiation through EU importers/distributors;
  3. Change export product form (low-concentration lysine 50%, lysine sulfate — outside duty scope);
  4. Market diversion (Middle East, Africa, South America, SE Asia).

Threonine no AD yet, but industry expects EU may launch similar investigation 2026-2027. Biggest export suspense.

11.3 Export rebate: 2025 policy lever

Export rebate rates currently:

  • Lysine HCl (HS 29224119): 9% (down from 13% in 2023);
  • Threonine, valine (HS 29224999): 9%;
  • MSG (HS 29224220): 9%;
  • Tryptophan: 9%.

2023 cut from 13% to 9% directly slashed industry profit (less RMB 40,000 per million yuan exported). Industry expects 9% maintained 2026-2027 — won't be cut further (anti-dumping aggravation), won't be raised back (avoid being defined as subsidy).

11.4 Carbon neutrality and green power: amino acid environmental cost

"Dual carbon" impact in three ways:

Carbon footprint requirement: Evonik's MetAMINO product carbon footprint 35% below industry average — selling point. EU and US downstream feed and meat firms increasingly under consumer pressure for "meat carbon footprint"; feed is 70%+ of that. China amino acid carbon footprint generally higher due to coal-heavy grid (China 60%+ thermal vs Europe US higher green). If overseas demand carbon labels on imported feed/amino acid, China export competitiveness suffers.

Green power conversion: heads already moving:

  • Meihua Tongliao/Baicheng: matching wind/PV;
  • Fufeng Wulanchabu/Xinjiang: wind grid;
  • Yipin Ningxia: wind/PV;
  • Huaheng Qinhuangdao: full green power procurement.

EU CBAM: from 2026 effective; not initial scope (cement, steel, aluminum, fertilizer, electricity, hydrogen) but expected 2027-2030 extension to chemicals and feed additives, creating new export barrier.

11.5 Synthetic biology national project

2025 MOST released "synthetic biology" key project — supports strain metabolic engineering, biomanufacturing process optimization, biodegradable materials. Hundreds of millions of yuan annually — direct R&D support for Huaheng, Meihua, Yipin synthetic biology.

Together: domestic policy environment is "encouragement-first, limited subsidy"; international is "trade barriers rising, green threshold higher." China amino acid must fight on "domestic demand drive + export defense + green upgrade + tech breakthrough" four fronts.

Chapter 12 Research Verdict: 3-5 Year "Four-Plus-Two" Outlook

Chapter 12 gives the research verdict. In the Industrial Research Institute's view, China amino acid 2026-2030 may evolve into a "four-plus-two" pattern — four bulk leaders dominate major products, two emerging poles break through in synthetic biology and pharmaceutical-grade.

12.1 Verdict 1: major product capacity remains surplus, price midpoint returns to cash cost

Next 3-5 years China lysine, threonine capacity continues to expand:

  • End-2026 lysine industry capacity ~4.1 mn t;
  • End-2028 ~4.5-4.8 mn t;
  • 2030 ~5 mn t;
  • Threonine 1.08 mn t → 1.5 mn t.

Demand (China + global) ~5-7% — visibly lagging. Result: major-product price midpoint at "cash cost + 10-20%":

  • Lysine RMB 8,500-10,500/t midpoint;
  • Threonine RMB 12,000-15,000/t midpoint;
  • Industry major-product margin 5-12% (far below 2021-2022 glory).

"Selling product earning spread" model gets harder — top firm real profit moves from "bulk spread" to "byproduct + unit consumption + export premium."

12.2 Verdict 2: small variety synthetic biology breakthrough supports profit

Next 3-5 years real industry profit increment from small varieties:

  • Valine: 19 mn → 30 mn t, RMB 30,000/t → 22,000-25,000/t;
  • Tryptophan: 5 mn → 9 mn t, RMB 80,000/t → 55,000-65,000/t;
  • Alanine: Huaheng 50k → 120k t, downstream into nylon 56, biodegradable plastic, cosmetic;
  • Arginine + isoleucine: high growth from supplements + BCAA sports nutrition;
  • BCAA trio: 15-20% growth/yr, substitution from 60% to 80%.

Small variety synthetic biology core dividends: strain barrier + high unit price + overseas untapped. Huaheng farthest along — expected next 5 years industry's highest-ROE player.

12.3 Verdict 3: pharmaceutical + medical aesthetic-grade sprint

Past 5 years' biggest increment:

  • China compound amino acid infusion 1.2 → 1.8 bn bottles/yr;
  • Substitution from <50% (2025) to 75% (2030);
  • Medical aesthetic amino acid (collagen peptide synthesis raw material) RMB 5 bn → 20 bn;
  • Supplement amino acid (BCAA, Arg, L-theanine) RMB 8 bn → 25 bn.

Meihua pharma amino acid 7.4 bn (2025) → 30-40 bn (2030) — biggest growth source.

12.4 Verdict 4: "Four-plus-two" pattern forms

Tianxia Gongchang Research Institute's "four-plus-two":

"Four" bulk leaders:

  • Meihua Biological: global #1 in lysine + threonine + MSG; 5-year core growth in pharma + high-value small + overseas;
  • Fufeng Group: global #1 MSG + global #1 xanthan + Kazakhstan overseas — 5-year core in overseas + food-grade extension;
  • Xinghu (Yipin): global #2 lysine + threonine + MSG + multi-base distribution + state-owned shareholder synergy;
  • CJ CheilJedang: only overseas player able to match Chinese tops — global small variety #1 + global brand customer network.

"Two" emerging poles:

  • Huaheng Biological: synthetic biology leader; alanine + valine + isoleucine + industrial serine small variety king; next 5 years from 80k to 300k t;
  • Angel Yeast: food + nutrition + bakery yeast kingdom; revenue from RMB 15 bn to 25 bn; broadest matrix, strongest brand.

12.5 Verdict 5: overseas capacity transfer accelerates

  • Fufeng Kazakhstan: 2026 commissioning, 2028 ramp;
  • Meihua potential SE Asia/Central Asia: 2028-2030;
  • Yipin potential SE Asia/Latin America: 2029-2031;
  • Huaheng potential Europe/North America R&D center: 2027-2029;
  • Angel global distribution network keeps expanding.

Strategic significance beyond "bypass anti-dumping" — making China amino acid from "capacity center" to "global production network center." Marker move of China Manufacturing 2.0.

12.6 Verdict 6: consolidation and M&A accelerate

Next 3-5 years industry consolidation expected:

  • Tier-2 exits/acquisitions: Shouguang Jinyumi, CJ Shenyang, Lianhua Health may be acquired by tops;
  • Upstream starch sugar firm synergies: amino acid firms may extend upstream;
  • Downstream feed firm reverse acquisitions: New Hope, Haid, Wens may reverse-acquire amino acid firms;
  • Cross-border consolidation: Chinese tops may acquire overseas exit assets.

Core drivers: scale effect, cash-cost line tier-2 exits, supply chain synergy advantage.

12.7 Verdict 7: strain and synthetic biology international output

Next 5 years: "strain internationalization" trend:

  • Chinese top strains licensed to SE Asia, South America, Africa;
  • Chinese synthetic biology platforms (Huaheng, Cathay, Bloomage, Sinophar) overseas factories;
  • Chinese research institutes (Meihua, Yipin, Huaheng research, Shanghai Jiao Tong, ECUST) joint R&D with overseas universities and firms;
  • Chinese amino acid standards (GB + group standards) increasingly aligning with ISO.

Symbolic shift: from "product output to technology output."

Combined: 2026-2030 China amino acid moves from "single-point cost competition" to "multi-front warfare" — bulk defends bottom, small varieties break through, pharma sprint, overseas building, synthetic biology breakthrough, international standard output, supply chain consolidation. Structural growth still possible, but "lying down to make money" era over.

Chapter 13 Risk Factors: Corn, Hogs, Trade, Anti-Absorption

Every research report must honestly list risks.

13.1 Risk 1: large corn price swings

Corn 40-60% of cost. Climate (drought/flood/frost) may cut yields and spike prices — 2022 corn peaked RMB 2,800/t. Policy (state reserve, import quotas, land policy). International (US crop, Brazil soybean substitution, Russia-Ukraine war impact on global supply). Biofuel (corn ethanol policy adjustment affecting demand structure).

If 2026-2030 corn rises >20%, amino acid tonne cost +800-1,200; some tier-2 forced exits. Biggest "cost-side risk."

13.2 Risk 2: hog stock cycle

Hogs = 40% of demand. Cycle 4-5 years (profit-expand-surplus-loss-cull-tight-profit). ASF, FMD may disrupt. Past cycle: 2018-2019 ASF, 2020-2021 windfall, 2022-2024 loss, 2025-2026 recovery. Next: 2027-2028 may surplus again.

If 2027-2028 hogs back to "surplus-loss," domestic amino acid demand -10-15% — biggest medium-term demand risk.

13.3 Risk 3: trade war and AD intensification

EU AD already; anti-absorption ongoing. Other potential:

  • EU threonine AD: industry expects 2026-2027;
  • US lysine AD: industry filing under review since May 2025;
  • Japan/Korea trade remedy: low probability but not excluded;
  • India/SE Asia local trade barriers: India frequent China chemical AD may extend to amino acid.

If next 5 years EU/US AD +20-30%, China exports may drop from 100-110 to 80-90k t, top firms revenue impact 10-15%.

13.4 Risk 4: overseas capacity political risk

Chinese amino acid overseas building faces:

  • Kazakhstan: geopolitically stable but Russia-Ukraine war creates uncertainty;
  • SE Asia (Vietnam, Indonesia): localization, land, labor policies may shift;
  • South America (Brazil, Argentina): big political cycles, anti-China sentiment volatility;
  • Africa: poor political stability, weak infrastructure.

These risks materialize over 3-5 years.

13.5 Risk 5: technological disruption

Synthetic biology era may disrupt traditional fermentation:

  • Cell-cultured meat commercialization: traditional meat demand drops, amino acid feed demand drops;
  • Plant protein substitution: pea protein, algae replace animal protein;
  • New protein sources: black soldier fly, fly larvae if scaled compete with feed amino acid;
  • New production: electrochemical synthesis, enzymatic catalysis may replace fermentation, lowering cost.

10-20 year horizon but quietly progressing. Chinese top firm R&D and synthetic biology essentially hedge against this long-term disruption.

13.6 Risk 6: environmental and dual-carbon cost

Dual-carbon pushes environmental/carbon cost continuously up:

  • Wastewater standards raise: tonne product +RMB 100-200;
  • Carbon tariff (CBAM extension): export cost +RMB 300-500/t;
  • Green retrofit: capex up, tonne cost +RMB 50-100;
  • Discharge license: some tier-2 forced exit.

Long-term "compliance cost" — unavoidable.

13.7 Risk 7: strain leak and IP

Strain top moat but easiest to "breach":

  • Core researchers jumping to competitors;
  • Industrial espionage;
  • Strain leaks via "legal" joint ventures;
  • Cyberattack stealing strain metabolic path data.

A major leak could erase a top firm's core moat, returning industry to price war.

13.8 Risk 8: macro and consumption downgrade

If China macro keeps weakening, downgrade transmits to:

  • Food industry MSG, YE demand down;
  • Supplement amino acid demand down;
  • Medical aesthetic amino acid demand down;
  • Overseas export competition intensifies (other export countries also face weak demand).

"Systemic macro risk" — unavoidable.

Combined: amino acid industry real risk isn't single "industry risk" but "cost-side + demand-side + political-side + tech-side" multi-line composite. Hence the industry's historically modest valuation — market deeply discounts long-term uncertainty.

Chapter 14 Data Sources and Research Institute Notes

This report's data base:

1. Listed company annual and quarterly reports

  • Meihua Biological (600873) 2024 annual, 2025 Q3 and annual;
  • Fufeng Group (0546.HK) 2024 and 2025 annual;
  • Xinghu Technology (600866) 2024 and 2025 annual + restructuring draft;
  • Angel Yeast (600298) 2025 interim, Q3;
  • Huaheng Biological (688639) 2024-2025 annual;
  • Ajinomoto (TYO:2802) FY2024 Q3;
  • CJ CheilJedang BIO disclosure;
  • Evonik Industries (XFRA:EVK) 2025 releases;
  • Daesang (KRX:001680) 2025 releases;
  • ADM Animal Nutrition public info;
  • Hisco, Green Cross, Fubon Pharma pharma-grade downstream annual reports.

2. Industry associations and statistics

  • China Fermentation Industry Association (CFIA);
  • China Feed Industry Association (CFIA);
  • China Customs import/export data (Lys, Thr, Val, Trp, MSG, YE HS codes);
  • National Bureau of Statistics grain, feed, livestock data;
  • Ministry of Agriculture and Rural Affairs feed industry public data;
  • Haid, New Hope, Wens feed sales disclosure.

3. Policy documents

  • Plan to Reduce Corn and Soybean Meal in Feed (2021);
  • Annual low-protein diet demonstration project lists;
  • Ministry of Finance + State Tax Administration 2023 export rebate adjustment;
  • MOST 2025 "Synthetic Biology" key project guide;
  • Commission Implementing Regulation (EU) 2025/1330;
  • Commission's April 2026 anti-absorption reopen announcement;
  • CBAM timeline and scope.

4. International data sources

  • FAO (UN Food and Agriculture Organization) global grain, livestock, feed statistics;
  • USDA global feed protein and corn data;
  • IFIF (International Feed Industry Federation);
  • Mordor Intelligence, Fortune Business Insights, IndexBox, Straits Research;
  • Reuters, Nikkei, Bloomberg amino acid industry coverage;
  • Kemiex, Feedinfo, Aquafeed.com specialty media;
  • EU Eurolysine company releases.

5. Technical literature

  • CAS Microbiology Institute, ECUST, Jiangnan University fermentation amino acid papers;
  • Acta Microbiologica Sinica, Industrial Microbiology, Food Science journals;
  • International journals: Journal of Industrial Microbiology and Biotechnology, Applied Microbiology and Biotechnology, Bioresource Technology.

6. Factory data

  • Factory data platform (https://www.tianxiagongchang.com) covers 4.8 million in-production factories — the downstream feed mills, food factories, pharma factories, chemical factories, new material factories named in this report come primarily from real factory data on this platform. The key difference from Qichacha, Tianyancha, Aiqicha "all-business databases" — those mix traders, shops, individual proprietors; this platform only includes real in-production manufacturing factories, materially raising data precision for ToB industrial research.

7. Research Institute note

This report was independently produced by the Industrial Research Institute (under the Inequality Technology team based in Huairou, Beijing). The methodology: "data-driven + factory-verified + multi-source cross-validation":

  • Data-driven: base data from above six sources, all with clear provenance;
  • Factory-verified: institute team conducts on-site visits to head firms' core bases periodically for first-line operational data;
  • Multi-source cross-validation: all key data points have at least two independent sources; single-source data tagged "to be verified."

The institute's industry research series publishes ~60-80 reports annually covering core manufacturing sectors. This is the twelfth deep-dive in the "chemical new materials + feed additives" track. Prior reports include "2026 China Feed and Livestock," "2026 China Condiment," "2026 China Chemical Materials," "2026 China Polysilicon," etc.

Views, judgments, forecasts in this report are for industry research and professional reference only — not investment advice. Some industry data are research-institute estimates from public information and may differ from authoritative releases. For citation, please attribute "Industrial Research Institute."

Reader feedback, data corrections, and deep collaboration may be sent via the publication platform.

About the platform: Tianxia Gongchang (https://www.tianxiagongchang.com) is China's B2B manufacturing platform covering 4.8 million in-production factories — products, capacity, upstream-downstream, customer relations data. Key difference from Qichacha, Tianyancha, Aiqicha "all-business databases" — only includes real in-production manufacturing factories, not traders, shops, individual proprietors. This filtering materially raises precision for ToB industrial sales, procurement, industry research. All factory data in this report comes from this platform.